Business
London Health Sciences Centre Launches as Newest Clinical Study Site for Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
TORONTO, ON / ACCESSWIRE / October 7, 2019 / Theralase® Technologies Inc. (" Ther...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"London Health Sciences Centre Launches as Newest Clinical Study Site for Phase II Non-Muscle Invasive Bladder Cancer Clinical StudyTORONTO, ON / ACCESSWIRE / October 7, 2019 / Theralase® Technologies Inc. (\"Theralase\" or the \"Company\") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (\"PDC\") and associated drug formulations, announced that London Health Sciences Centre (\"LHSC\") Research Ethics Board (\"REB\") has approved the commencement of a Phase II Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Clinical Study to enroll and treat patients who present with Carcinoma In-Situ (\"CIS\") and who are considered Bacillus Calmette-Guerin (\"BCG\")-Unresponsive or are intolerant to BCG Therapy (\"Study II\").LHSC is recognized as one of Canada's leading cancer research centres ranking, in the top ten of Canada's research hospitals. LHSC's research institute is affiliated with the University of Western Ontario and is responsible for training the next generation of medical professionals, while leading Ontario research into the latest medical technologies.Dr. Joseph Chin, MD, FRSC, Professor of Urology & Oncology, at the University of Western located in London Ontario, stated that \"Theralase's Phase II NMIBC Clinical Study, utilizing their ground-breaking technology, provides a significant number of patients with bladder cancer, who have essentially exhausted all of their management options, short of more invasive surgery with another chance at a cure and preservation of their bladder.\"With the addition of LHSC, the Company now has three sites open for patient enrollment and treatment; specifically, LHSC, University Health Network (\"UHN\") and McGill University Health Centre (\"MUHC\"). All sites are actively recruiting and screening new patients for enrollment in Study II. In addition, the Company has approximately six clinical study sites located in Canada and the US that are at various stages of the on-boarding process. The Company is specifically targeting strategic clinical sites throughout Canada and the US (subject to FDA Investigational New Drug (\"IND\") approval) that serve large populations or have the demographics to support patient enrollment and treatment. The Company anticipates that patient enrollment a...